Results 51 to 60 of about 3,559 (85)

Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single-Centre Real-World Experience. [PDF]

Cancer Rep (Hoboken)
Çınar OE, Kanat A, Erer K, Şahin R, Eren EE, Yıldızhan E.   +5 more
europepmc   +1 more source

Modular access to saturated bioisosteres of anilines via photoelectrochemical decarboxylative C(sp³)-N coupling. [PDF]

Nat Commun
Yuan KN, Zhuang H, Wei J, Shen Y, Yao HQ, Li MH, Xu LL, Shang M.   +7 more
europepmc   +1 more source

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. [PDF]

Hematol Oncol
Medawar G, Anoma JS, Hill E, Tharakan S, Sastow DL, Lok V, Hahn SB, Chen S, Kehoe T, Ramasamy C, Guetta-Weiss J, Meleveedu K, Lin C, Swoboda DM, Tremblay D, Coltoff A.   +15 more
europepmc   +1 more source

Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome. [PDF]

Ann Hematol
Cardinali V, Coiro S, Martelli MP, Sportoletti P.   +3 more
europepmc   +1 more source

Synthesis and Reactivity of Triphosphaallyl Cation Stabilized by N-Heterocyclic Carbenes. [PDF]

Chemistry
Frötschel-Rittmeyer J, Hennersdorf F, Fidelius J, Sala C, Ziegler C, Holthausen M, Schwedtmann K, Wolf R, Weigand JJ.   +8 more
europepmc   +1 more source

Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia. [PDF]

Br J Haematol
Crespo-García E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, Martinez-Verbo L, Esteller M.   +5 more
europepmc   +1 more source

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +1 more source

Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage. [PDF]

Blood
Ngo S, D'Agostino G, Papazoglou D, Mohamad Nor F, Finsterbusch K, Habel K, Ferrelli A, Anjos-Afonso F, Bonnet D.   +8 more
europepmc   +1 more source

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. [PDF]

Blood Adv
Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar A, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS.   +17 more
europepmc   +1 more source

Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia. [PDF]

Blood Adv
Castillo JJ, Guijosa A, Allan JN, Siddiqi T, Advani RH, Flynn CA, Meid K, Budano N, Nguyen J, Ramirez-Gamero A, Tsakmaklis N, Hunter ZR, Patterson CJ, Treon SP, Sarosiek S.   +14 more
europepmc   +1 more source